 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | S-531011 / Shionogi
Phase classification, Combination therapy, Monotherapy, Checkpoint inhibition, Metastases: aCCeleR8-001: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 25, 2024
P1/2, N=274, Recruiting, Sponsor: Shionogi
Phase classification: P1b/2 --> P1/2
- | S-531011 / Shionogi
Journal: S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells. (Pubmed Central) - Jul 8, 2023
S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing anti-tumor immunity without severe side effects in the clinical setting.
- |||| S-531011 / Shionogi
Enrollment open, Combination therapy, Monotherapy, Checkpoint inhibition, IO biomarker, Metastases: aCCeleR8-001: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 30, 2022
P1b/2, N=274, Recruiting, Sponsor: Shionogi Inc.
These results suggest that S-531011 is a promising drug for inducing anti-tumor immunity without severe side effects in the clinical setting. Not yet recruiting --> Recruiting
- S-531011 / Shionogi
S-531011, a novel anti-human CCR8 antibody: Antibody screening and evaluation of biological profiles (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_624;
Conclusions We develop S-531011, a novel anti-human CCR8 humanized antibody which could selectively recognize and deplete tumor infiltrating Tregs. Based on our pre-clinical data, S-531011 has strong anti-tumor effect and we expect that it might be a potent novel tumor immuno-therapeutic agent with fewer side effect.
- S-531011 / Shionogi
S-531011, a novel anti-human CCR8 antibody: anti-tumor responses through depletion of tumor-infiltrating CCR8-positive Tregs (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_616;
On the other hand, S-531011 didn’t reduce Tregs in human PBMC. Conclusions S-531011 is a promising drug which has a strong antitumor effect by depleting tumor-infiltrating CCR8+ Tregs, as a not only monotherapy but also combination therapy with other immune checkpoint inhibitors.